A5045937368- Pharmaceutical Practices and Patient Outcomes
- Medication Adherence and Compliance
- Pharmaceutical studies and practices
- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
- Biosimilars and Bioanalytical Methods
- Healthcare Policy and Management
- Antibiotic Use and Resistance
- Pharmaceutical industry and healthcare
- Rheumatoid Arthritis Research and Therapies
- Chronic Lymphocytic Leukemia Research
- Pharmacovigilance and Adverse Drug Reactions
- Problem and Project Based Learning
- Monoclonal and Polyclonal Antibodies Research
- Opioid Use Disorder Treatment
- Immunodeficiency and Autoimmune Disorders
- Athletic Training and Education
- Heparin-Induced Thrombocytopenia and Thrombosis
- Poisoning and overdose treatments
- Pharmacy and Medical Practices
- Multiple Myeloma Research and Treatments
- Lipoproteins and Cardiovascular Health
- Multiple Sclerosis Research Studies
- Diabetes Management and Education
- Patient-Provider Communication in Healthcare
University of Illinois Chicago
2013-2023
American Association of Colleges of Pharmacy
2014
IS practice
1995-2013
University of Illinois Urbana-Champaign
2012
Illinois College
1992
Historical trends and factors likely to influence future pharmaceutical expenditures are discussed, projections made for drug spending in 2017 nonfederal hospitals, clinics, overall (all sectors).Drug expenditure data through calendar year 2016 were obtained from the QuintilesIMS National Sales Perspectives database analyzed. Other that may hospitals clinics 2017, including new approvals patent expirations, also reviewed. Expenditure sectors) based on a combination of quantitative analyses...
Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and predict growth in drug spending 2020 the United States, with a focus on nonfederal hospital clinic sectors. Methods Historical were assessed by examining data purchases from manufacturers using IQVIA National Sales Perspectives database. Factors hospitals clinics reviewed, including new approvals, patent expirations, potential policies or legislation....
Abstract Purpose Results of the first ASHP National Survey Health-System Specialty Pharmacy Practice are presented. Methods A sample 230 leaders in health-system specialty pharmacies were contacted by email and invited to participate a survey hosted using an online application. The was compiled from member lists, through review data other surveys indicating presence pharmacies, outreach organizational leaders. response rate 53.0%. Most dispense 30,000 or fewer prescriptions per year, have...
An analysis of trends in U.S. pharmaceutical spending is presented, including projections for drug expenditures nonfederal hospital and clinic settings 2015.Prescription expenditure data through September 2014 were obtained from the IMS Health National Sales Perspectives database analyzed descriptively. Other factors that may influence prescription hospitals clinics 2015, new approvals patent expirations, analyzed. Expenditure based on a combination quantitative qualitative analyses expert...
Abstract Purpose Historical trends and factors likely to influence future pharmaceutical expenditures are discussed, projections made for drug spending in 2019 nonfederal hospitals, clinics, overall (all sectors). Methods Drug expenditure data through calendar year 2018 were obtained from the IQVIA National Sales Perspectives database analyzed. New approvals, patent expirations, other that may hospitals clinics also reviewed. Expenditure sectors) a combination of quantitative analyses expert...
Historical trends and factors likely to influence future pharmaceutical expenditures are discussed, projections made for drug spending in 2018 nonfederal hospitals, clinics, overall (all sectors).Drug expenditure data through calendar year 2017 were obtained from the IQVIA (formerly QuintilesIMS) National Sales Perspectives database analyzed. New approvals, patent expirations, other that may hospitals clinics also reviewed. Expenditure sectors) based on a combination of quantitative analyses...
Tumor necrosis factor (TNF)-alpha inhibitors and other biologic response modifiers (BRMs) are frequently used to treat a variety of inflammatory diseases. Use these agents may increase risk serious infections, malignancies, complications such as worsening symptoms heart failure or demyelinating disease. Because risks, baseline assessment routine monitoring have been recommended, but standardized guidelines for yet be established.To measure the compliance with recommended safety in Clinical...
The impact of the market entry adalimumab biosimilars on clinical practices and specialty pharmacies is explained. A roadmap also provided for how pharmacists can successfully navigate this landscape.Biosimilars have previously been introduced as a mechanism to help curb biologic expenditures, with undergoing an abbreviated regulatory approval process that focuses biosimilarity generating product competition. Adalimumab currently leading in biologics market, approximately $20 $30 billion...
Over the past decade, several challenges to drug safety have emerged.1 As concerns about existing drugs continue and as more complex biologicals are introduced, need manage mitigate risk while maintaining access innovative therapies becomes increasingly important.2–8 The Food Drug Administration (FDA), through its Risk Evaluation Mitigation Strategy (REMS) program, now mandates management patient strategies for selected therapies.9 This article reviews REMS structure selection process...
To describe a pharmacist-managed virtual consult service practice model for rheumatology patients and evaluate its initial impact on compliance with institutional critical care guidelines biologic response modifiers (BRMs).Pharmacologic of rheumatologic conditions often revolves around the use BRMs. While these drugs are generally well tolerated, nearly all them carry risks serious adverse events. The severity possible problems necessitates thorough ongoing clinical workup. Based results...
An integrated effort to maintain continued access pharmacy services and prescribed medications for patients in an inner-city community before during the implementation of Medicare prescription drug benefit is described.An academic medical center college a culturally diverse, Chicago created strategy provide uninterrupted all their Part D eligible patients, particularly those dual Medicaid Medicare, transition from D, effective January 1, 2006. The percentage dual-eligible population at...